Copenhagen Life Science Advisors
We are a dedicated life sciences consultancy company with years of experience from the pharmaceutical, biotech and medtech industries, as well as experience from working in and with life science venture capital.
We work closely with our clients to secure a detailed understanding of the specific challenges at hand in order to provide actionable solutions.
In addition to our native network in Denmark, we have a strong network across the life sciences industry and venture firms in Europe and the US.
Jarne Elleholm, founder and Managing Partner, has more than 20 years’ experience in the life science industry with strong record of achievements in commercialization of drugs and medtech products, as well as in fundraising for early stage life science companies.
Prior to establishing Copenhagen Life Science Advisors, he worked in the venture capital industry as partner in Vækstfonden and as Managing Partner in Inventure Capital. During this period he worked closely with 12 life science portfolio companies as active lead investor and board member or chairman.
From 2005-07 he served as CEO of biotech company Aresa A/S, where he built up the organization and completed an IPO raising more than DKK 50 million.
Prior experience includes European Vice President for Whatman International (now part of GE Healthcare) and CEO for Lundbeck Ltd. UK where he successfully launched several pharmaceutical products.
Jarne Elleholm currently services as Chairman of the Board of Scandinavian Micro Biodevices and Chairman of the Board of Meta-IQ. Prior positions include Chairman of Fluxome Sciences, FCMB, RSP Systems and Medotech, and board member of CytoVac, Action Pharma, Quantibact, Proxeon and Liplasome Pharma.
Jarne holds an M. Com from Copenhagen Business School and an MBA from INSEAD.
Torben Skarsfeldt, Managing Director, has more than 30 years experience in the life science industry with a strong record of achievements in research and development.
Prior to joining Copenhagen Life Science Advisors he worked within research, business development and project management at H. Lundbeck A/S handling both small molecules as well as biological products. Furthermore, as a consultant he has orchestrated successful regulatory pathways from preclinical into IND in the US.
Torben Skarsfeldt I currently CEO and owner of Pharma Guidance ApS, and serves as Scandinavian Advisor for the Ferghana Partners Group. He is member of the KLIFO Drug Development Counsel and a Board member of ArrayDignostics. He previously served 16 years as member of the Supervisor Board of H. Lundbeck A/S in Denmark.
Torben holds a M.Sc. a D.Sc from Copenhagen University.